Prospera Financial Services Inc Boosts Stock Holdings in Novo Nordisk A/S $NVO

Prospera Financial Services Inc boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 5.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 441,858 shares of the company’s stock after buying an additional 21,063 shares during the quarter. Prospera Financial Services Inc’s holdings in Novo Nordisk A/S were worth $22,483,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Guerra Advisors Inc purchased a new position in Novo Nordisk A/S in the third quarter valued at $25,000. Strengthening Families & Communities LLC purchased a new position in Novo Nordisk A/S in the third quarter valued at $30,000. WealthCollab LLC increased its holdings in Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after buying an additional 260 shares during the last quarter. American National Bank & Trust purchased a new position in Novo Nordisk A/S in the fourth quarter valued at $28,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new position in Novo Nordisk A/S in the fourth quarter valued at $29,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on NVO. The Goldman Sachs Group reissued a “neutral” rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price on the stock in a report on Tuesday, March 3rd. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Wolfe Research began coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They issued a “peer perform” rating for the company. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: European regulators recommended approval of Novo Nordisk’s Wegovy 7.2 mg pen, with trial data showing up to 20.7% mean weight loss, strengthening the company’s obesity-drug pipeline and supporting future EU sales. Article Title
• Positive Sentiment: The CHMP also recommended approval for Novo Nordisk’s Wegovy pill, potentially making it the first oral GLP-1 obesity drug in the EU and broadening the company’s treatment options. Article Title
• Positive Sentiment: Reuters reported Novo is using AI to speed drug development and expand its role in India, which could help it bring new products to market faster and regain momentum in obesity. Article Title
• Neutral Sentiment: Industry chatter about Lilly’s obesity-drug breakthrough and reports that both Lilly and Novo drugs may have cancer-prevention benefits highlight strong demand in the class, but also underscore intensifying competition and a larger long-term market. Article Title
• Negative Sentiment: Eli Lilly’s retatrutide posted about 28% weight loss in late-stage testing, setting a new benchmark that increases pressure on Novo Nordisk to keep innovating in obesity and GLP-1 therapies. Article Title

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $44.91 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44. The company has a market capitalization of $200.52 billion, a PE ratio of 10.54, a P/E/G ratio of 4.01 and a beta of 0.77. The company has a fifty day moving average of $40.29 and a two-hundred day moving average of $46.46.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The company had revenue of $10.85 billion during the quarter. As a group, analysts expect that Novo Nordisk A/S will post 3.46 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.